Veracyte - VCYT Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VCYT shares.
View VCYT analyst ratings or view top-rated stocks.

7 brokerages have issued 1-year price targets for Veracyte's stock. Their VCYT share price forecasts range from $22.00 to $50.00. On average, they anticipate the company's share price to reach $34.86 in the next year. This suggests a possible upside of 30.7% from the stock's current price.
View analysts price targets for VCYT or view top-rated stocks among Wall Street analysts.

Veracyte's stock was trading at $23.73 at the start of the year. Since then, VCYT shares have increased by 12.4% and is now trading at $26.67.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our VCYT earnings forecast.

Veracyte, Inc. (NASDAQ:VCYT) issued its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.06. The biotechnology company earned $60.37 million during the quarter, compared to analysts' expectations of $54.66 million. Veracyte had a negative net margin of 15.25% and a negative trailing twelve-month return on equity of 4.03%. During the same quarter last year, the firm posted ($0.08) earnings per share.

Veracyte issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $288.00 million-$293.00 million, compared to the consensus revenue estimate of $277.79 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Veracyte's stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (11.57%), Sumitomo Mitsui Trust Holdings Inc. (4.27%), Fisher Asset Management LLC (2.91%), New York State Common Retirement Fund (1.26%), EFG Asset Management North America Corp. (0.41%) and Essex Investment Management Co. LLC (0.19%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John Walter Hanna Jr, John Walter Hanna, Jr, Karin Eastham, Keith Kennedy, Kevin K Gordon, Marc Stapley, Mark Ho and Robert S Epstein.
View institutional ownership trends.

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VCYT stock can currently be purchased for approximately $26.67.

Veracyte (NASDAQ:VCYT) has a market capitalization of $1.91 billion and generates $219.51 million in revenue each year. The biotechnology company earns $-75,560,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

The company employs 761 workers across the globe.

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.veracyte.com. The biotechnology company can be reached via phone at (650) 243-6300, via email at keith@veracyte.com, or via fax at 650-243-6301.